Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856439 | 0.98 | ALDH1A1 (0.48) | LMNAALDH1A1CA12CA7CA14 | |
| SCHEMBL16372265 | 0.98 | ALDH1A1 (0.48) | LMNAALDH1A1CA12CA7CA14 | |
| SCHEMBL20372908 | 0.98 | ALDH1A1 (0.48) | LMNAALDH1A1CA12CA7CA14 | |
| SCHEMBL7297373 | 0.94 | ALDH1A1 (0.50) | LMNAALDH1A1CA12CA7CA14 | |
| SCHEMBL4547019 | 0.86 | ALDH1A1 (0.61) | LMNAALDH1A1CA12CA7CA14 | |
| SCHEMBL17832935 | 0.84 | THRB (0.46) | LMNAALDH1A1CYP1A2THRB | |
| SCHEMBL10722736 | 0.84 | FAAH (0.48) | ALDH1A1KDM4EL3MBTL1THRBFAAH | |
| SCHEMBL10721831 | 0.84 | FAAH (0.48) | ALDH1A1KDM4EL3MBTL1THRBFAAH | |
| SCHEMBL7122564 | 0.84 | FAAH (0.48) | ALDH1A1KDM4EL3MBTL1THRBFAAH | |
| SCHEMBL22600626 | 0.82 | LMNA (0.42) | LMNAALDH1A1CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988477-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2021-04-27 | — | — | US | disclosed |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988477-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, EIF2AK1 | LMNA 3908/4885ALDH1A1 4754/4885CA12 4498/4885 |
| US-20190233425-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | LMNA 3246/4885ALDH1A1 4414/4885CA12 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.